 |
市场调查报告书
商品编码
1983180
创伤后压力症候群 (PTSD) 治疗市场：按药物类别、给药途径、年龄层、分销管道和地区划分Post-traumatic Stress Disorder Treatment Market, By Drug Class, By Route of Administration, By Age Group By Distribution Channel, By Geography |
||||||
价格
简介目录
2026年，创伤后压力症候群（PTSD）治疗市场规模预计为12.59亿美元，预计到2033年将达到17.835亿美元。预计从2026年到2033年，该市场将以5.1%的复合年增长率成长。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 12.59亿美元 |
| 业绩数据週期： | 2020-2024 | 预测期： | 2026-2033 |
| 2026-2033年预测期间的复合年增长率： | 5.10% | 2033年市场规模预测： | 17.835亿美元 |
创伤后压力症候群（PTSD）是一种精神疾病，可能发生在经历创伤性事件的人身上，例如自然灾害、危及生命的事件、车祸或性虐待。 PTSD的症状可能在三个月甚至一年后才会出现。许多PTSD患者会出现侵入性记忆、逃避行为、负面思考模式改变、情绪和生理反应异常等症状。例如，亲人的突然离世可能会诱发某些人的PTSD。 PTSD患者的危险感知能力会显着增强。根据美国国家创伤后压力症候群中心估计，约有15%的越战老兵和约12%的海湾战争老兵患有PTSD。美国精神医学会指出，女性罹患PTSD的可能性是男性的两倍。治疗创伤后压力症候群的常用药物包括抗忧郁症、舍曲林、Fluoxetine和帕罗西汀。
市场动态
主要市场公司加大创伤后压力症候群（PTSD）治疗的研发活性化，预计将在预测期内推动全球PTSD治疗市场成长。例如，2021年12月，製药公司Jazz Pharmaceuticals plc.宣布其首批患者已完成入组，该试验旨在评估JZP150的安全性和有效性。 JZP150是一种First-in-Class的小分子化合物，目前正在开发用于治疗成人PTSD患者。 JZP150是一种高选择性脂肪酸酰胺水解酵素（FAAH）抑制剂，旨在解决PTSD的根本原因（恐惧消退和固着障碍）以及焦虑、失眠和噩梦等相关症状。
本次调查的主要特点。
- 本报告详细分析了 2022 年至 2030 年预测期间全球创伤后压力症候群 (PTSD) 治疗市场的规模，以 2021 年为基准年。
- 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
- 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数分析了全球创伤后压力症候群 (PTSD) 治疗市场的主要企业：公司概况、财务绩效、产品系列、企业发展区域、分销策略、关键发展和策略。
- 透过利用本报告中的见解，企业负责人和经营团队将能够就未来的产品发布、政府主导的倡议、技术升级、市场扩张和行销策略做出明智的决策。
- 本报告面向该行业的众多相关人员，包括投资者、产品製造商、经销商、供应商、研究和咨询公司、新参与企业和金融分析师。
- 相关人员可以透过分析全球创伤后压力症候群 (PTSD) 治疗市场中使用的各种策略矩阵来促进决策。
目录
第一章：研究目标与前提条件
- 研究目标
- 前提
- 简称
第二章 市场范围
- 报告摘要
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章：市场动态、监管与趋势分析
- 市场动态
- 促进因素
- 抑制因子
- 市场机会
- 影响分析
- 市场趋势
- 主要进展
- 产品核准
- 合作关係、併购
- 监理情势
- PEST分析
- 波特五力分析
- 流行病学
- 强大的管道分析
第四章 全球创伤后压力症候群（PTSD）治疗市场：依药物类别划分，2026-2033年
- 抗忧郁症
- 抗焦虑药物
- 抗高血压药物
- 单胺氧化酵素（MAO）抑制剂
- 抗精神病药物或第二代抗精神病药物（SGOs）
- β阻断剂
- 其他（苯二氮平类药物及其他）
第五章 全球创伤后压力症候群（PTSD）治疗市场：依给药途径划分，2026-2033年
- 口服
- 肠外
- 鼻内
第六章 全球创伤后压力症候群（PTSD）治疗市场：依年龄组别划分，2026-2033年
- 儿童
- 成人
- 老年人
第七章 全球创伤后压力症候群（PTSD）治疗市场：依通路划分，2026-2033年
- 医院药房
- 零售药房
- 网路药房
第八章 全球创伤后压力症候群（PTSD）治疗市场：按地区划分，2026-2033年
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
- 中东
- GCC
- 以色列
- 其他中东国家
- 非洲
- 北非
- 中非
- 南非
第九章 竞争情势
- 热图分析
- 市占率分析
- 公司简介
- Jazz Pharmaceuticals plc.
- Madrigal Mental Care
- Allergan PLC
- Otsuka Pharmaceutical Co., Ltd.
- apex laboratories Pvt. Ltd.
- H. Lundbeck A/S（Lundbeck）
- Neurovation Labs, Inc.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Sun Pharmaceuticals Pvt Ltd
- Bristol-Myers Squibb
- Johnson and Johnson
- Pfizer Inc.
- Aurobindo Inc.
- Amneal Pharmaceuticals LLC
- Teva Pharmaceuticals Industries Ltd.
- Mylan Pharmaceuticals（Viatris Inc.）
第十章
- 参考
- 调查方法
- 关于本公司
简介目录
Product Code: CMI4433
Post-traumatic Stress Disorder Treatment Market is estimated to be valued at USD 1,259 Mn in 2026 and is expected to reach USD 1,783.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,259 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 1,783.5 Mn |
Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc. Symptoms of PTSD may generate after three months or even after a year. Most of the patients suffering from PTSD show symptoms like intrusive memories, avoidance, negative changes in thinking and changes in emotional and physical reactions. For instance, sudden death of a loved one may cause PTSD in some people. People with PTSD have heightened sense of danger. According to the U.S. National centre for PTSD, it is estimated that about 15% of the veterans of Vietnam War and 12% of gulf war veterans have PTSD. According to American Psychiatric Association, women are twice likely to get PTSD as compared to men. Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.
Market Dynamics
Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period. For instance, in December 2021, Jazz Pharmaceuticals plc. a pharmaceutical company, announced that the company had enrolled its first patient in Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme Fatty Acid Amide Hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patient's associated symptoms such as anxiety, insomnia, and nightmares.
Key features of the study
- This report provides an in-depth analysis of the global post-traumatic stress disorder treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global post-traumatic stress disorder treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Jazz Pharmaceuticals plc., Madrigal Mental Care, Allergan PLC, Otsuka Pharmaceutical Co., Ltd., apex laboratories Pvt. Ltd., H. Lundbeck A/S (Lundbeck), Neurovation Labs, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceuticals Industries Ltd., and Mylan Pharmaceuticals (Viatris Inc.)
- Insights from this report would allow marketers and management authorities of companies to make an informed decision for their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global post-traumatic stress disorder treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global post-traumatic stress disorder treatment market
Market Segmentation
- By Drug Class
- Antidepressants
- Anti-anxiety
- Antihypertensive
- Monoamine Oxidase (MAOs)
- Antipsychotics or Second-Generation Antipsychotics (SGOs)
- Beta-Blockers
- Others (Benzodiazepines and Others)
- By Route of Administration
- Oral
- Parenteral
- Nasal
- By Age Group
- Pediatric
- Adult
- Geriatric
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Jazz Pharmaceuticals plc.
- Madrigal Mental Care
- Allergan PLC
- Otsuka Pharmaceutical Co., Ltd.
- apex laboratories Pvt. Ltd.
- Lundbeck A/S (Lundbeck)
- Neurovation Labs, Inc.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Sun Pharmaceuticals Pvt Ltd
- Bristol-Myers Squibb
- Johnson and Johnson
- Pfizer Inc.
- Aurobindo Inc.
- Amneal Pharmaceuticals LLC
- Teva Pharmaceuticals Industries Ltd.
- Mylan Pharmaceuticals (Viatris Inc.)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Post-traumatic Stress Disorder Treatment Market, By Drug Class, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Anti-anxiety
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Antihypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Monoamine Oxidase (MAOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Antipsychotics or Second-Generation Antipsychotics (SGOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Beta-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others (Benzodiazepines and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Post-traumatic Stress Disorder Treatment Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Post-traumatic Stress Disorder Treatment Market, By Age Group, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
8. Global Post-traumatic Stress Disorder Treatment Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Jazz Pharmaceuticals plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Madrigal Mental Care
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Allergan PLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- apex laboratories Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- H. Lundbeck A/S (Lundbeck)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Neurovation Labs, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceuticals Pvt Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aurobindo Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan Pharmaceuticals (Viatris Inc.)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
